Kate Cunningham

Company: Personalis

Job title: Field Applications Scientist

Seminars:

Ultrasensitive MRD Detection as a Biomarker for Patient Selection, Drug Efficacy, and Recurrence 9:30 am

NeXT Personal is an analytically validated, tumor-informed liquid biopsy assay with consistent ultrasensitive 1-3 PPM detection Ultrasensitive MRD detection at baseline, landmark, and longitudinal timepoints across multiple cancer indications demonstrates an ability to accurately identify responders quickly, as well as advantages over commonly used endpoint measurements NeXT Personal can accelerate decisions in drug development through…Read more

day: Conference Day 2